Get started
ORAMED PHARMORAMED PHARMORAMED PHARM

ORAMED PHARM

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

ORMP chart


Full chart

ORMP upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪366.61 M‬ ILS
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
22.1
Basic EPS (TTM)
0.4 ILS
Net income (FY)
‪20.06 M‬ ILS
Revenue (FY)
‪4.87 M‬ ILS
Shares float
‪34.04 M‬
Beta (1Y)
1.06

Employees


Employees (FY)
15
Change (1Y)
−2 −11.76%
Revenue / Employee (1Y)
‪324.36 K‬ ILS
Net income / Employee (1Y)
‪1.34 M‬ ILS

About Oramed Pharmaceuticals Inc.


Sector
Health Technology
CEO
Nadav Kidron
Headquarters
New York
Website
oramed.com
Founded
2002
FIGI
BBG00H3P5B58
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ORMP news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ORMP is 886.5 ILA — it has increased by 0.75% in the past 24 hours. Watch ORAMED PHARM stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TASE exchange ORAMED PHARM stocks are traded under the ticker ORMP.
ORMP stock has fallen by −0.51% compared to the previous week, the month change is a 5.59% rise, over the last year ORAMED PHARM has showed a 10.92% increase.
We've gathered analysts' opinions on ORAMED PHARM future price: according to them, ORMP price has a max estimate of 1,216.64 ILA and a min estimate of 1,216.64 ILA. Watch ORMP chart and read a more detailed ORAMED PHARM stock forecast: see what analysts think of ORAMED PHARM and suggest that you do with its stocks.
ORMP reached its all-time high on Nov 3, 2021 with the price of 9,856.0 ILA, and its all-time low was 653.7 ILA and was reached on Jan 29, 2023. View more price dynamics on ORMP chart.
See other stocks reaching their highest and lowest prices.
ORMP stock is 5.44% volatile and has beta coefficient of 1.06. Track ORAMED PHARM stock price on the chart and check out the list of the most volatile stocks — is ORAMED PHARM there?
Today ORAMED PHARM has the market capitalization of ‪348.94 M‬, it has decreased by −4.79% over the last week.
Yes, you can track ORAMED PHARM financials in yearly and quarterly reports right on TradingView.
ORAMED PHARM is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
ORMP earnings for the last quarter are −1.79 ILA per share, whereas the estimation was 0.02 ILA resulting in a ‪−9.70 K‬% surprise. The estimated earnings for the next quarter are −0.07 ILA per share. See more details about ORAMED PHARM earnings.
ORAMED PHARM revenue for the last quarter amounts to 0.00 ILA, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ORMP net income for the last quarter is ‪−73.21 M‬ ILS, while the quarter before that showed ‪34.81 M‬ ILS of net income which accounts for −310.29% change. Track more ORAMED PHARM financial stats to get the full picture.
No, ORMP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 15.00 employees. See our rating of the largest employees — is ORAMED PHARM on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ORAMED PHARM EBITDA is ‪−47.94 M‬ ILS, and current EBITDA margin is ‪−1.16 K‬%. See more stats in ORAMED PHARM financial statements.
Like other stocks, ORMP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ORAMED PHARM stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ORAMED PHARM technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ORAMED PHARM stock shows the sell signal. See more of ORAMED PHARM technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.